Hereditary angioedema (HAE) research hub

A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.

This study is looking at how well different versions of a new medicine for hereditary angioedema (HAE) are absorbed by the body. Healthy volunteers will take a single dose of the medicine and have their blood checked. We want to find the best way to give this new treatment.

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

This study looks at how well a medicine called lanadelumab (Takhzyro) works for children aged 2-11 with a rare swelling condition called Hereditary Angioedema (HAE). We're checking how long children go without swelling attacks when taking this medicine in their daily lives, using existing medical records.

A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal on the Bioavailability of a 40 mg Extended-Release (XR) Deucrictibant Oral Formulation Administered as a Single Dose.

This study is looking at how a new medicine, deucrictibant, is absorbed by the body. We're testing if eating a big, fatty meal changes how much of the medicine gets into your system when you take it as an extended-release tablet in healthy people.

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

This study is an extension of a previous trial for people with a condition called hereditary angioedema (HAE). It's looking at the long-term safety and how well a medicine, ADX-324, works for HAE types 1 and 2. Participants would have already taken part in the earlier study.

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

This study is looking at a new tablet, deucrictibant, to see if it can help prevent swelling attacks in people with Hereditary Angioedema (HAE). It includes adults and children aged 12 and over, comparing the new drug to a dummy pill (placebo).

A Study of Navenibart in Participants With Hereditary Angioedema

This study is testing a new medicine, navenibart, for people with Hereditary Angioedema (HAE). Researchers want to see if it safely and effectively prevents swelling attacks in adults and teenagers with HAE.

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

This study looks at how a medicine called lanadelumab helps teenagers and adults in the UK with a swelling condition called Hereditary Angioedema (HAE). We're comparing their HAE attacks before and after starting this treatment to see how well it works.

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

This study looks at a new medicine called navenibart for people with hereditary angioedema (HAE). It checks how safe and effective it is over a long time. Only people who were in a previous study with this medicine can join.

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

This study is looking at a new tablet, deucrictibant, for teenagers and adults with Hereditary Angioedema (HAE). It aims to see if taking it daily can safely and effectively reduce painful swelling attacks over a long period.

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

This study looks at a new daily medicine called deucrictibant for people aged 12 and over with hereditary angioedema (HAE). It's for long-term use to treat sudden swelling attacks, including dangerous swelling in the throat. Researchers want to see how safe and effective it is over time.

A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants with Hereditary Angioedema (The ALPHA-STAR Trial)

A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age